J
James M. Robertson
Researcher at Applied Biosystems
Publications - 4
Citations - 142
James M. Robertson is an academic researcher from Applied Biosystems. The author has contributed to research in topics: Genome & Variable number tandem repeat. The author has an hindex of 4, co-authored 4 publications receiving 141 citations.
Papers
More filters
Book ChapterDOI
An Introduction to PCR Primer Design and Optimization of Amplification Reactions
Journal ArticleDOI
Duchenne/Becker muscular dystrophy carrier detection using quantitative PCR and fluorescence-based strategies.
Elaine S. Mansfield,James M. Robertson,Roger V. Lebo,Lucero My,Mayrand Pe,Eric F. Rappaport,T Parrella,M. Sartore,Saul Surrey,Paolo Fortina +9 more
TL;DR: This work determined DMD/BMD carrier status in 24 unrelated families using a fluorescent fragment analyzer and described two alternative fluorescent labeling strategies, each with approximately 1,000-fold greater sensitivity than ethidium bromide staining, which can be used to quantify the products of multiplex PCR.
Journal ArticleDOI
Forensic applications of a rapid, sensitive, and precise multiplex analysis of the four short tandem repeat loci HUMVWF31/A, HUMTH01, HUMF13A1, and HUMFES/FPS
TL;DR: A system of four short tandem repeat loci (HUMVWF31A, HUMTH01, HUMF13A1, and HUMFES/FPS) has been tested in co‐amplification with forensic DNA samples, and the fluorescence‐based system facilitates large‐scale databasing, because the PCR products run off the gel, allowing more than one set of samples to be analyzed per run.
Journal ArticleDOI
Fluorescence-based, multiplex allele-specific PCR (MASPCR) detection of the ΔF508 deletion in the cystic fibrosis transmembrane conductance regulator (CFTR) gene
Paolo Fortina,Rebecca Conant,T Parrella,Eric F. Rappaport,Thomas F. Scanlin,Elias Schwartz,James M. Robertson,Saul Surrey +7 more
TL;DR: The approach simplifies diagnosis of the most common mutation in the CFTR gene, and holds promise for a multiplex allele-specific, fluorescence-tagged gene amplification strategy for detection of additional CF mutations which may result in more cost-effective testing without increasing the risk of missed or erroneous diagnoses.